- Home
- ATYR vs OLMA Comparison
ATYR vs OLMA Comparison
Compare ATYR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- OLMA
- Stock Information
- Founded
- ATYR 2005
- OLMA 2006
- Country
- ATYR United States
- OLMA United States
- Employees
- ATYR N/A
- OLMA N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- OLMA Health Care
- Exchange
- ATYR Nasdaq
- OLMA Nasdaq
- Market Cap
- ATYR 327.0M
- OLMA 289.0M
- IPO Year
- ATYR 2015
- OLMA 2020
- Fundamental
- Price
- ATYR $2.96
- OLMA $3.33
- Analyst Decision
- ATYR Strong Buy
- OLMA Strong Buy
- Analyst Count
- ATYR 6
- OLMA 4
- Target Price
- ATYR $18.60
- OLMA $26.75
- AVG Volume (30 Days)
- ATYR 1.5M
- OLMA 910.6K
- Earning Date
- ATYR 03-13-2025
- OLMA 03-18-2025
- Dividend Yield
- ATYR N/A
- OLMA N/A
- EPS Growth
- ATYR N/A
- OLMA N/A
- EPS
- ATYR N/A
- OLMA N/A
- Revenue
- ATYR $235,000.00
- OLMA N/A
- Revenue This Year
- ATYR $1,387.23
- OLMA N/A
- Revenue Next Year
- ATYR $873.22
- OLMA N/A
- P/E Ratio
- ATYR N/A
- OLMA N/A
- Revenue Growth
- ATYR N/A
- OLMA N/A
- 52 Week Low
- ATYR $1.42
- OLMA $3.28
- 52 Week High
- ATYR $4.66
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- ATYR 37.05
- OLMA 24.82
- Support Level
- ATYR $3.20
- OLMA $3.28
- Resistance Level
- ATYR $3.94
- OLMA $4.26
- Average True Range (ATR)
- ATYR 0.25
- OLMA 0.33
- MACD
- ATYR -0.08
- OLMA -0.05
- Stochastic Oscillator
- ATYR 9.33
- OLMA 3.40
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.